secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-12-15T23:59:59+00:00
Accession:  0000950170-23-070582
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CHMP positive opinion for CASGEVY conditional EU approval in sickle cell and beta thalassemia
--------------------------------------------------------------------------------

- EMA's CHMP adopted positive opinion for conditional approval of CASGEVY (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta thalassemia.
- CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals.
- European Commission decision expected in February 2024; conditional marketing authorizations are valid one year, renewable annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023070582/0000950170-23-070582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023070582/crsp-20231215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-070582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer